In brief: Spinraza recommended for funding on NHS

Spinraza recommended for funding on NHS
Credit: Biogen

Spinraza has been recommended for funding on the NHS in the UK, Biogen has confirmed.

The positive recommendation from NICE is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.

SMA is a rare, debilitating and life-threatening disease that results in severe, progressive muscular atrophy and weakness.

“This is a momentous occasion for patients and their families and the result of a strong collaboration between Biogen, NICE, NHS and the SMA community,” said Chirfi Guindo, Executive Vice President, Global Product Strategy and Commercialisation at Biogen.